屏风生脉胶囊联合单硝酸异山梨酯治疗冠心病心绞痛的临床研究

目的 探讨屏风生脉胶囊联合单硝酸异山梨酯片治疗冠心病心绞痛的临床疗效。方法 选取2022年1月—2023年6月河池市宜州区人民医院共计120例冠心病心绞痛患者，以计算机随机排列法分为对照组（60例）和治疗组（60例）。对照组口服单硝酸异山梨酯片，1片/次，2次/d。治疗组在对照组治疗的基础上口服屏风生脉胶囊，3粒/次，3次/d。两组治疗1个月。观察两组的心绞痛和心电图疗效，比较两组的心绞痛症状、心功能指标、血清指标。结果 治疗后，治疗组的心绞痛总有效率比对照组高，差异显著（93.33% vs 80.00%，P＜0.05）。治疗后，治疗组心电图总有效率比对照组高，差异显著（85.00% vs 70.00%，P＜0.05）。治疗后，两组疼痛程度、持续时间、发作频率显著降低（P＜0.05），治疗组的心绞痛症状低于对照组（P＜0.05）。治疗后，两组的射血分数（EF）、心指数（CI）、每搏输出量（SV）比治疗前大（P＜0.05），治疗组的EF、CI、SV比对照组大（P＜0.05）。治疗后，两组的血清肌钙蛋白Ⅰ（cTnI）、心型脂肪酸结合蛋白（H-FABP）、肿瘤坏死因子受体相关因子6（TRAF6）、脂蛋白磷脂酶A2（Lp-PLA2）水平比治疗前小（P＜0.05），治疗组的血清指标比对照组小（P＜0.05）。结论 冠心病心绞痛患者经屏风生脉胶囊联合单硝酸异山梨酯治疗，明显提高心绞痛和心电图疗效，降低心绞痛症状，改善心功能，降低心肌炎症损伤。

Clinical study on Pingfeng Shengmai Capsules combined with isosorbide mononitrate in treatment of angina pectoris of coronary heart disease

Objective To investigate the clinical effect of Pingfeng Shengmai Capsules combined with Isosorbide Mononitrate Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (120 cases) with angina pectoris of coronary heart disease in the People’s Hospital Yizhou from January 2022 to June 2023 were divided into control and treatment groups according to the computer random arrangement method, and each group had 60 cases. Patients in the control group were po administered with Isosorbide Mononitrate Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Pingfeng Shengmai Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the efficacies of angina pectoris and electrocardiographic were evaluated, and the angina pectoris pain symptoms, cardiac function indicators, and serum indicators in two groups were compared. Results After treatment, the total effective rate of angina pectoris in the treatment group was higher than that in the control group, with a significant difference (93.33% vs 80.00%, P < 0.05). After treatment, the total effective rate of electrocardiogram in the treatment group was higher than that in the control group, with a significant difference (85.00% vs 70.00%, P < 0.05). After treatment, pain degree, duration, and frequency in two groups were significantly decreased (P < 0.05), and the angina pectoris symptoms in the treatment group were lower than those in the control group (P < 0.05). After treatment, EF, CI, and SV in two groups were higher than those before treatment (P < 0.05), and EF, CI, and SV in the treatment group were higher than those in the control group (P < 0.05). The serum levels of cTnI, H-FABP, TRAF6, and Lp-PLA2 in two groups were lower than those before treatment (P < 0.05), and the serum indexes in the treatment group were lower than those in the control group (P < 0.05). Conclusion Pingfeng Shengmai Capsules combined with Isosorbide Mononitrate Tablets can significantly improve the efficacy of angina pectoris and electrocardiogram, reduce the symptoms of angina pectoris, improve heart function and reduce myocardial inflammation.